Connect Biopharma Holdings (CNTB) Return on Sales (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted Return on Sales of 1.15% for Q1 2026, up 86.76% sequentially from 8.67% in Q4 2025.

Connect Biopharma Holdings (CNTB) Return on Sales (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported Return on Sales for 3 years, with the latest figure at 1.15% in Q1 2026.

Quarterly Return on Sales changed N/A year-over-year to 1.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.77% (changed N/A YoY) and the FY2025 annual result came in at 8.67%, down 866.0% from the prior year.
Return on Sales advanced to 1.15% in Q1 2026 per CNTB's latest filing, from 8.67% in the prior quarter.
Over five years, Return on Sales peaked at 0.11% in Q3 2024 and troughed at 10.75% in Q3 2025.
A 3-year average of 3.91% and a median of 1.92% in 2026 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 854 bps in 2025, down 1064 bps in 2025.
Over 3 years, Return on Sales stood at 0.13% in 2024, then slumped by 6694 bps to 8.67% in 2025, then soared by 87 bps to 1.15% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 1.15%, 8.67%, and 10.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	0.00%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	-0.06%

Download Data